Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 800
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
163% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 32
90% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 60
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
20% more capital invested
Capital invested by funds: $1.72B [Q3] → $2.06B (+$341M) [Q4]
18% more funds holding
Funds holding: 264 [Q3] → 312 (+48) [Q4]
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
13.52% less ownership
Funds ownership: 92.93% [Q3] → 79.41% (-13.52%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
9%
upside
Avg. target
$8.33
52%
upside
High target
$11
100%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Morgan Stanley Vikram Purohit 33% 1-year accuracy 2 / 6 met price target | 45%upside $8 | Equal-Weight Maintained | 10 Apr 2025 |
Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target | 100%upside $11 | Buy Reiterated | 8 Apr 2025 |
Leerink Partners Mani Foroohar 20% 1-year accuracy 3 / 15 met price target | 9%upside $6 | Market Perform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 11 articles about RXRX published over the past 30 days
Neutral
The Motley Fool
1 day ago
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Artificial intelligence (AI) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations; governmental institutions are doing the same.
Neutral
PRNewsWire
4 days ago
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
PHILADELPHIA , April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows.
Positive
Zacks Investment Research
5 days ago
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Positive
The Motley Fool
1 week ago
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Shares of Recursion Pharmaceuticals (RXRX 17.52%) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.
Neutral
Zacks Investment Research
1 week ago
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Neutral
GlobeNewsWire
1 week ago
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world's largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas.
Negative
The Motley Fool
2 weeks ago
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
Neutral
GlobeNewsWire
2 weeks ago
Recursion to Participate in Upcoming Investor Conference
Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference — Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.
Negative
The Motley Fool
2 weeks ago
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET.
Positive
The Motley Fool
2 weeks ago
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.
Charts implemented using Lightweight Charts™